JAK1 and poikiloderma with neutropenia: Numerous case reports have shown the successful treatment of refractory PN with tofacitinib (JAK1/3 inhibitor), baricitinib (JAK1/2 inhibitor), and upadacitinib (JAK1 inhibitor) (115–124).